Related Experiment Videos
[Cholestyramine in the treatment of acute bacterial diarrhea in infants]
Insights
Cholestyramine improved infant infectious diarrhea by reducing stool output and improving stool appearance. This treatment was well-tolerated, showing no adverse effects in infants with dehydration.
Area of Science:
- Pediatrics
- Gastroenterology
- Infectious Diseases
Background:
- Infectious diarrhea and dehydration are significant health concerns in infants.
- Standard treatment involves rehydration, refeeding, and antibiotics like furazolidone.
- Exploring adjunct therapies to improve outcomes is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of cholestyramine as an adjunct therapy for infectious diarrhea in infants.
- To assess the impact of cholestyramine on clinical progress and fecal characteristics.
Main Methods:
- A randomized controlled trial involving 32 infants with infectious diarrhea and dehydration.
- Comparison between a standard treatment group and a group receiving standard treatment plus cholestyramine.
- Analysis of clinical progress, stool features, transit time, fecal pH, reducing substances, volume, water, sodium, potassium, and chloride excretion.
Main Results:
- Cholestyramine group demonstrated earlier improvement in stool appearance.
- Reduced fecal volume and water excretion were observed in the cholestyramine group.
- Diminished sodium and potassium elimination in feces, with similar chloride excretion between groups.
Conclusions:
- Cholestyramine is a safe and effective adjunct therapy for infectious diarrhea in infants.
- It significantly improves stool characteristics and reduces fluid and electrolyte loss.
- Excellent tolerance and absence of side effects highlight its therapeutic potential.
Abstract:
32 infants admitted to Hospital "Roberto del Río" with infectious diarrhea and dehydration were assigned random to two groups, one of them receiving the usual therapeutic regimen of rehydration, refeeding and furazolidone and the other group the same treatment plus cholestyramine. The patients were studied with balance technique on days 1st, 3rd., and 5th. after admission, analyzing clinical progress, features of the stools, total digestive transit time, pH of the feces and the presence of reducing substances, volume of the stools, water excretion and sodium, potassium and chloride elimination in the feces. The patients receiving cholestyramine showed an earlier improvement in the appearance of the stools, less excretion of feces and water and diminished sodium and potassium elimination. Chloride excretion was similar in both groups. Cholestyramine tolerance was excellent. No side effects or complications were observed.